Media coverage about DaVita (NYSE:DVA) has been trending somewhat positive this week, Accern reports. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. DaVita earned a media sentiment score of 0.08 on Accern’s scale. Accern also gave headlines about the company an impact score of 47.1766008517513 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the headlines that may have impacted Accern’s rankings:
- DaVita (DVA) Expected to Post Earnings of $0.98 Per Share (americanbankingnews.com)
- Form 4 DAVITA INC. For: May 14 Filed by: BERG CHARLES (streetinsider.com)
- DaVita (DVA) Director Sells $22,392.50 in Stock (americanbankingnews.com)
- DaVita Teammates Volunteer with Bridge of Life and the Syrian American Medical Society to Support Health Care … (prnewswire.com)
- DaVita Teammates Volunteer with Bridge of Life and the Syrian American Medical Society to Support Health Care Needs of Syrian Refugees in Jordan (finance.yahoo.com)
Several analysts have issued reports on the company. SunTrust Banks reaffirmed a “hold” rating and issued a $80.00 target price on shares of DaVita in a research note on Wednesday, February 14th. Robert W. Baird set a $97.00 target price on DaVita and gave the stock a “buy” rating in a research note on Tuesday, February 13th. Finally, Zacks Investment Research lowered DaVita from a “buy” rating to a “hold” rating in a research note on Tuesday, February 13th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating, four have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $79.30.
DVA stock traded up $0.75 during midday trading on Thursday, hitting $67.58. The company had a trading volume of 1,023,900 shares, compared to its average volume of 1,566,581. The company has a debt-to-equity ratio of 1.94, a quick ratio of 2.90 and a current ratio of 2.94. DaVita has a 52 week low of $66.30 and a 52 week high of $66.97. The company has a market capitalization of $11.57 billion, a P/E ratio of 20.36, a PEG ratio of 0.97 and a beta of 1.10.
DaVita (NYSE:DVA) last announced its quarterly earnings data on Thursday, May 3rd. The company reported $1.05 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.92 by $0.13. DaVita had a return on equity of 13.84% and a net margin of 2.94%. The firm had revenue of $2.85 billion during the quarter, compared to the consensus estimate of $2.79 billion. During the same quarter in the previous year, the company posted $0.79 earnings per share. The business’s revenue was up 8.3% on a year-over-year basis. equities analysts predict that DaVita will post 4.1 earnings per share for the current year.
DaVita Company Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.